Baader Bank Aktiengesellschaft Sells 271 Shares of Eli Lilly and Company (NYSE:LLY)

Baader Bank Aktiengesellschaft trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 4,290 shares of the company’s stock after selling 271 shares during the period. Baader Bank Aktiengesellschaft’s holdings in Eli Lilly and Company were worth $3,312,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Foster & Motley Inc. lifted its position in shares of Eli Lilly and Company by 60.1% during the 4th quarter. Foster & Motley Inc. now owns 1,556 shares of the company’s stock worth $1,201,000 after buying an additional 584 shares during the period. Manning & Napier Advisors LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at $507,000. Plimoth Trust Co. LLC boosted its stake in shares of Eli Lilly and Company by 0.8% in the 4th quarter. Plimoth Trust Co. LLC now owns 5,271 shares of the company’s stock valued at $4,069,000 after purchasing an additional 44 shares in the last quarter. VanderPol Investments L.L.C. grew its holdings in shares of Eli Lilly and Company by 7.0% in the 4th quarter. VanderPol Investments L.L.C. now owns 381 shares of the company’s stock worth $294,000 after purchasing an additional 25 shares during the last quarter. Finally, Ibex Wealth Advisors acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $8,982,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $811.61 on Friday. The firm has a fifty day moving average of $782.29 and a two-hundred day moving average of $845.82. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The stock has a market capitalization of $770.48 billion, a price-to-earnings ratio of 87.74, a PEG ratio of 1.71 and a beta of 0.41. Eli Lilly and Company has a 52 week low of $637.00 and a 52 week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. During the same period in the previous year, the company posted $0.10 EPS. The company’s quarterly revenue was up 20.4% compared to the same quarter last year. As a group, equities research analysts predict that Eli Lilly and Company will post 12.85 EPS for the current year.

Eli Lilly and Company declared that its board has authorized a stock buyback program on Monday, December 9th that allows the company to buyback $15.00 billion in outstanding shares. This buyback authorization allows the company to purchase up to 2% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.74%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 56.22%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Sanford C. Bernstein started coverage on shares of Eli Lilly and Company in a research report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price target on the stock. Wells Fargo & Company decreased their price target on Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating on the stock in a research report on Tuesday. Truist Financial lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research report on Thursday, October 10th. Deutsche Bank Aktiengesellschaft decreased their target price on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a report on Monday, November 4th. Finally, Wolfe Research began coverage on Eli Lilly and Company in a report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price target for the company. Five analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $997.22.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.